FOR SEBORRHEIC DERMATITIS
ZORYVE® IT
RELIEVE IT
ANYWHERE
ZORYVE treats it, wherever patients need it,
with an easy, once-daily, steroid-free topical1
Symptoms illustrated. Not an actual patient.
ZORYVE is for topical use only and not for ophthalmic, oral, or intravaginal use.1
ZORYVE treats it, wherever patients need it, with an easy, once-daily, steroid-free topical1
ZORYVE is for topical use only and not for ophthalmic, oral, or intravaginal use.1
SIMPLIFY SEBORRHEIC DERMATITIS CONTROL WITH ZORYVE (zor-EEV)
77% of patients achieved IGA Success at Week 8, some as early as Week 2.1,2
RAPID, RELIABLE RESULTS ANYWHERE1,2
SEE RESULTSCONSISTENTLY WELL TOLERATED AND SAFE1,3
REVIEW SAFETY PROFILEPATIENT-FRIENDLY FOAM FORMULATION FOR EASY, LONG-TERM DISEASE CONTROL1,4
DISCOVER THE UNIQUE FORMULATIONIGA Success = Achievement of Clear/Almost Clear and a ≥2-grade improvement from baseline.
IGA = Investigator Global Assessment.
ZORYVE foam has the potential to become the standard of care for seborrheic dermatitis.”
—Arcutis Chief Medical Officer Patrick Burnett, MD, PhD, FAAD
Actor portrayal
Committed to affordable patient access across all indications
One ZORYVE Direct Savings Program helps eligible, commercially insured patients get access and start ZORYVE treatment quickly and easily*†
Patient Access Support
Savings Program
Adherence Support
*Prescriptions will be delivered to the patient 1–2 days after processing.
†Subject to eligibility criteria and maximum program limitation. This offer is not valid for patients without commercial drug insurance or whose prescription claims are eligible to be reimbursed, in whole or in part, by any government program. Please see Terms and Conditions.